Develops targeted cancer therapies, focusing on improving drug delivery for solid tumors.
RenovoRx, Inc. is an innovative clinical-stage biopharmaceutical company dedicated to advancing therapies aimed at combatting solid tumors. At the forefront of its development pipeline is RenovoGem, a pioneering drug and device combination featuring intra-arterial gemcitabine delivered via RenovoCath. Currently, RenovoGem is undergoing Phase III clinical trials for the treatment of locally advanced pancreatic cancer, addressing a critical unmet medical need in oncology.
Founded in 2009 and headquartered in Los Altos, California, RenovoRx, Inc. continues to push boundaries in cancer treatment innovation. The company's mission centers on harnessing advanced technologies to enhance therapeutic outcomes and improve the quality of life for patients battling solid tumors.
With a commitment to scientific excellence and patient-focused innovation, RenovoRx, Inc. exemplifies leadership in the biopharmaceutical sector. By leveraging strategic partnerships and cutting-edge research, the company remains poised to make significant strides in the field of oncology, offering hope to patients and healthcare providers worldwide.